Using the Best Science to Save Lives
While HIV prevalence is low in North American and Western and Central Europe, the situation is different in other parts of the world, especially in East and Southern Africa.1
- There were 1.8 million new HIV infections in 2016, 1.2 million of these occurred in sub-Saharan Africa.2
- 45% of all new HIV infections were in key populations, many of these individual lack safe and dignified access to essential HIV services.
- More than half of men under the age of 35 do not know their HIV status.3
- The number of 15- to 24-year-olds in sub-Saharan Africa has doubled since the start of the epidemic, and girls and young women account for 74% of new HIV infections among adolescents in the region.4
- What is HIV and how do you get it?
- How can HIV be prevented? (PrEP, PMTCT, VMMC)
- Who is getting infected? (difference is epidemic—key populations)
- Why HIV testing is important?
- How is HIV treated?
Frequently Asked Questions
- Can HIV be cured?
- How can HIV be prevented?
- What does circumcision have to do with HIV?
Continue Reading: Jhpiego’s HIV/AIDS Resources
Where We Make an Impact[Map]
How We Make an Impact
HIV Testing Services
HIV testing is the critical entry point to life-saving HIV care and treatment for people living with HIV. These services are also important for linking people who test negative to prevention services, such as pre-exposure prophylaxis (PrEP), voluntary medical male circumcision, condoms and risk reduction counseling.
Since 2001, Jhpiego has supported HIV testing service programs in 34 countries, providing 10 million people with testing services, and linking more than 240,000 people living with HIV to care and treatment services. We have achieved this by:
- Supporting UNAIDS 90-90-90 goals through partnerships with local governments and communities, and delivery of high-quality HIV testing services with active linkage to HIV care and treatment for people living with HIV.
- Designing targeted programs that expand access to HIV testing services and uptake among hard-to-reach populations, including key populations, men, adolescent girls and young women, children and partners of people living with HIV, through health facility- and community-based testing services.
- Using evidence-based and innovative approaches for reaching target populations, including integrated and provider-initiated testing services, mobile testing, workplace testing, partner notification, couples testing and HIV self-testing.
Prevention of new HIV infections is vital to achieving epidemic control. Jhpiego has championed bringing biomedical HIV prevention interventions to scale, including voluntary medical male circumcision (VMMC)—a safe, minor procedure that reduces the risk of female-to-male HIV transmission by 70%5—and PrEP—a daily pill demonstrated to be more than 90% effective in preventing HIV.6
Since 2003, Jhpiego has emerged as one of the few international organizations with the knowledge and experience to support, strengthen, and scale up VMMC services while ensuring safety and quality. Since 2008, more than 2.5 million men and boys have accessed VMMC through Jhpiego-supported services across 12 of the 158 VMMC focus countries.
- Reaching individuals in greatest need with high-impact HIV prevention interventions
- Offering service delivery models that maximize accessibility, safety, and acceptability, especially for hard-to-reach populations
Prevention of Mother-to-Child Transmission (PMTCT)
With effective interventions, fewer than 5% of HIV-positive women will pass the virus to their newborns during pregnancy, childbirth or breastfeeding.7
- Integrating care for mother and baby—early infant diagnosis and PMTCT/antiretroviral therapy (ART) services in a single appointment
- Using effective tracking systems—early infant diagnosis for up to 8 weeks
- Increase male involvement/engagement—antenatal care as an entry point to attract men to health services
Care and Treatment
Jhpiego is helping individuals learn their HIV status and linking them to care and treatment. Our support for essential services includes clinical care, diagnosis and management of opportunistic infections, viral load testing and psychosocial support in the community. Currently, 74,000+ people are receiving antiretroviral treatment through Jhpiego-supported programs.
- Supporting adoption of “Treat All” in countries where we work
- Promoting patient-centered ART solutions—community ART and multi-month dispensing for stable clients on ART
- Supporting adherence and retention through efforts like peer support groups and intensive support for clients with high viral loads (> 1,000 copies/mL)
- Facilitating prompt switching to second-line therapy for clients with confirmed treatment or virological failure
Care and Treatment
2. UNAIDS. 2016. Global HIV Statistics. Geneva: UNAIDS.
3. PHIA Project. 2016. “Malawi Population-Based HIV Impact Assessment: MPHIA 2015–2016.” New York: ICAP at Columbia University; PHIA Project. 2016. “Zambia Population-Based HIV Impact Assessment: MPHIA 2015–2016.” New York: ICAP at Columbia University; PHIA Project. 2016. “Zimbabwe Population-Based HIV Impact Assessment: MPHIA 2015–2016.” New York: ICAP at Columbia University.
4. WHO. 2016. “TUBERCULOSIS: Global Tuberculosis Report 2016.” Geneva: WHO
5. Lei JH, et al. 2015. “Circumcision Status and Risk of HIV Acquisition during Heterosexual Intercourse for Both Males and Females: A Meta-Analysis.” PLoS ONE 10(5): e0125436. doi: 10.1371/journal.pone.0125436.
6. Baeten JM, et al. 2012. “Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.” N Engl J Med 2012;367:399-410. DOI: 10.1056/NEJMoa1108524; Grant RM, et al. 2010. “Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.” N Engl J Med 2010;363(27):2587-99.
7. UNAIDS. 2013. Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS.